1. Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y, Kaya BY, Sandikci M, Ozdil B (2010) No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev 11 (4): 1051–1058.
2. Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, Al-Jomah N, Mohamed GH, Moorji A, Uddin S, Siraj AK, Al-Kuraya K (2008) Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma 49 (1): 122–129.
3. Alexandrie AK, Nyberg F, Warholm M, Rannug A (2004) Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 13 (6): 908–914.
4. Asher G, Lotem J, Kama R, Sachs L, Shaul Y (2002a) NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 99 (5): 3099–3104.
5. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y (2002b) Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci USA 99 (20): 13125–13130.